Compare GPRO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | BDSX |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 143.2M |
| IPO Year | 2014 | 2020 |
| Metric | GPRO | BDSX |
|---|---|---|
| Price | $1.12 | $15.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 7.0M | 68.2K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $651,542,000.00 | $88,499,000.00 |
| Revenue This Year | $23.14 | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.59 | $0.26 |
| 52 Week High | $3.05 | $20.21 |
| Indicator | GPRO | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 60.90 |
| Support Level | $0.94 | $13.46 |
| Resistance Level | $1.17 | $16.38 |
| Average True Range (ATR) | 0.11 | 1.01 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 44.74 | 63.07 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.